Thrombosis, Anti-thrombotic Therapy and Cancer

• REFERENCES

• 1 Trousseau A. Phlegmasia alba dolens. Clinique Medicale de Paris. New Sydenham Society 1865; 03: 94.
• 2 Broze GJ. The tissue factor pathway of coagulation. In: Bloom AL, Forbes CD, Thomas DP, Tuddenham EGD. (eds.) Haemostasis and Thrombosis. Churchill Livingstone: 1994: 349-77.
• 3 Gordon SG, Cross BA. A factor X activating cysteine protease from malignant tissue. J Clin Invest 1981; 67: 1665-71.
• 4 Pineo GF, Regoeczi E, Hatton MW, Brain MC. The activation of coagulation by extracts of mucus: a possible pathway of intra-vascular coagulation accompanying adenocarcinomas. J Lab Clin Med 1973; 82: 255-66.
• 5 O’Meara RAQ, Thornes RD. Some properties of the cancer coagulative factor. Irish Medical Sei 1961; 423: 106-12.
• 6 Van De Water L, Tracy PB, Aronson D, Mann KG, Dvorak HF. Tumour cell generation of thrombin via functional prothrom-binase complex. Cancer Res 1985; 45: 5521-5.
• 7 Rao LV. Tissue factor as a tumor procoagulant. Cancer Metastasis Rev 1992; 11: 249-66.
• 8 Edgington TS, Mackman N, Brand K, Ruf W. The structural biology of expression and function of tissue factor. Thromb Haemost 1991; 66: 67-79.
• 9 Bazan JF. Structural design and molecular evolution of a cytokine receptor superfamily. Proc Natl Acad Sei USA 1990; 87: 6934-8.
• 10 Gasic GP, Arenas CP, Gasic TB, Gasic GJ. Coagulation factors X, Xa, and protein S as potent mitogens of cultured aortic smooth muscle cells. Proc Natl Acad Sei USA 1992; 89: 2317-20.
• 11 McNamara CA, Sarembock IJ, Gimple LW, Fenton JW 2, Coughlin SR, Owens GK. Thrombin stimulates proliferation of cultured rat aortic smooth muscle cells by a proteolytically activated receptor (see comments). J Clin Invest 1993; 91: 94-8.
• 12 Vu TK, Hung DT, Wheaton VI, Coughlin SR. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 1991; 64: 1057-68.
• 13 Sun NC, McAttee WM, Hum GJ. et al. Haemostatic abnormalities in malignancy, a prospective study of one hundred and eight patients. Am J Clin Pathol 1979; 71: 10.
• 14 Carlsson S. Fibrinogen degradation products in serum from patients with cancer. Acta Chir Scand 1973; 139: 499-502.
• 15 Bick RL. Coagulation abnormalities in malignancy: A review. Seminars in Thrombosis and Haemostasis 1992; 18: 353-72.
• 16 Davis RB, Theologides A, Kennedy BJ. Comparative studies of blood coagulation and platelet aggregation in patients with cancer and nonmalignant diseases. Ann Intern Med 1969; 71: 67-80.
• 17 Miller SP, Sanchez-Avalos J, Stefanski T, Zuckerman L. Coagulation disorders in cancer. I. Clinical and laboratory studies. Cancer 1967; 20: 1452-65.
• 18 Rickies FR, Levine M, Edwards RL. Hemostatic alterations in cancer patients. Cancer Metastasis Rev 1992; 11: 237-48.
• 19 Kakkar AK, De Ruvo N, Tebbutt S, Williamson RCN. Extrinsic pathway activation with elevated tissue factor and factor Vila. Lancet 1995; 346: 1004-5.
• 20 Mannucci PM. Markers of hypercoagulability in cancer patients. Haemostasis 1997; 25-31.
• 21 Zacharski LR, Moritz TE, Baczek LA, Rickies FR, Edwards RL, Forman WB. et al. Effect of mopidamol on survival in carcinoma of the lung and colon: final report of Veterans Administration Cooperative Study No. 188. J Natl Cancer Inst 1988; 80: 90-7.
• 22 Falanga A, Ofosu FA, Cortelazzo S, Delaini F, Consonni R, Caccia R. et al. Preliminary study to identify cancer patients at high risk of venous thrombosis following major surgery. Br J Haematol 1993; 85: 745-50.
• 23 Prandoni P, Lensing AW, Buller HR, Cogo A, Prins MH, Cattelan AM. et al. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med 1992; 327: 1128-33.
• 24 Monreal M, Lafoz E, Casals A, Inaraja L, Montserrat E, Callejas JM. et al. Occult cancer in patients with deep venous thrombosis. A systematic approach. Cancer 1991; 67: 541-5.
• 25 Nordstrom M, Lindblad B, Anderson H, Bergqvist D, Kjellstrom T. Deep venous thrombosis and occult malignancy: an epidemiological study. BMJ 1994; 308: 891-4.
• 26 Rajan R, Levine M, Gent M, Hirsh J, Geerts W, Skingley P. et al. The occurrence of subsequent malignancy in patients presenting with deep vein thrombosis: results from a historical cohort study. Thromb Haemost 1998; 79: 19-22.
• 27 Kakkar VV, Howe CT, Nicolaides AN, Renney JT, Clarke MB. Deep vein thrombosis of the leg. Is there a “high risk” group? Am J Surg 1970; 120: 527-30.
• 28 Walsh JJ, Bonnar J, Wright FW. A study of pulmonary embolism and deep leg vein thrombosis after major gynaecological surgery using labelled fibrinogen-phlebography and lung scanning. J Obstet Gynaecol Br Commonw 1974; 81: 311-6.
• 29 InternationalMulticentre Trial. Prevention of fatal postoperative pulmonary embolism by low doses of heparin. Lancet 1975; ii: 45-51.
• 30 Rahr HB, Sorensen JV. Venous thromboembolism and cancer. Blood Coagul Fibrinolysis 1992; 03: 451-60.
• 31 Clagett GP, Anderson Jr FA, Heit J, Levine MN, Wheeler HB. Prevention of venous thromboembolism. Chest 1995; 108: 312-34.
• 32 Weiss RB, Tormey DC, Holland JF, Weinberg VE. Venous thrombosis during multimodal treatment of primary breast carcinoma. Cancer Treat Reports 1981; 65: 677-9.
• 33 Wall JG, Weiss RB, Norton L, Perloff M, Rice MA, Korzun AH. et al. Arterial thrombosis associated with adjuvant chemotherapy for breast carcinoma: a Cancer and Leukemia Group B Study. Am J Med 1989; 87: 501-4.
• 34 Levine MN, Gent M, Hirsh J, Arnold A, Goodyear MD, Hryniuk W. et al. The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. N Engl J Med 1988; 318: 404-7.
• 35 Saphner T, Tormey DC, Gray R. Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer. J Clin Oncol 1991; 09: 286-94.
• 36 Pritchard KI, Paterson AH, Paul NA, Zee B, Fine S, Pater J. Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group. J Clin Oncol 1996; 14: 2731-7.
• 37 Fisher B, Redmond C. Legault-Poisson Postooperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive node breast cancer patients aged 50 years and older with tumours responsive to tamoxifen: results from the national surgical adjuvant breast and bowel project B16. J Clin Oncol 1990; 08: 1005-18.
• 38 Rifkin SE, Constantino J, Redmond C. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node negative breast cancer who have estrogen-receptor positive tumours. N Eng J Med 1989; 320: 479-84.
• 39 Fisher B, Costantino J, Redmond C, Poisson R, Bowman D, Couture J. et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors (Prior annotation incorrect). N Engl J Med 1989; 320: 479-84.
• 40 Goodnough LT, Saito H, Manni A, Jones PK, Pearson OH. Increased incidence of thromboembolism in stage IV breast cancer patients treated with a five-drug chemotherapy regimen. A study of 159 patients. Cancer 1984; 54: 1264-8.
• 41 von Templehoff GF, Dietrich M, Niemann F, Schneider D, Hommel G, Heilmann L. Blood coagulation and thrombosis in patients with ovarian malignancy. Thromb Haemost 1997; 77: 456-61.
• 42 Barbui T, Finazzi G, Grassi A, Marchioli R. Thrombosis in cancer patients treated with hematopoietic growth factors-a metaanalysis. On behalf of the Subcommittee on Haemostasis and Malignancy of the Scientific and Standardization Committee of the ISTH. Thromb Haemost 1996; 75: 368-71.
• 43 Bern MM, Lokich JJ, Wallach SR. et al. Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomised prospective trial. Ann Intern Med 1990; 112: 423-8.
• 44 Monreal M, Alastrue A, Rull M, Mira X, Muxart J, Rosell R. et al. Upper extremity deep venous thrombosis in cancer patients with venous access devices-prophylaxis with a low molecular weight heparin (Fragmin). Thromb Haemost 1996; 75: 251-3.
• 45 Kakkar AK, Lemoine NR, Scully MF, Tebbutt S, Williamson RC. Tissue factor expression correlates with histological grade in human pancreatic cancer. Br J Surg 1995; 82: 1101-4.
• 46 Callender NS, Varki N, Rao LVM. Immuno-histochemical identification-of tissue factor in solid tumours. Cancer 1992; 70: 1194-201.
• 47 Kakkar AK, Chinswangwatanakul V, Lemoine N, Williamson RCN. Overexpression of tissue factor enhances growth of human pancreatic tumours. Brit J Surg 84 (51) 54.
• 48 Zhang Y, Deng Y, Luther T, Muller M, Ziegler R, Waldherr R. et al. Tissue factor controls the balance of angiogenic and anti-angiogenic properties of tumour cells in mice. J Clin Invest 1994; 94: 1320-7.
• 49 Ruf W, Mueller BM. Tissue factor in cancer angiogenesis and metastasis. Curr Opin Hematol 1996; 03: 379-84.
• 50 Haralaboupoulos GC, Grant DS, Kleinman HK, Maragoudakis ME. Thrombin promotes endothelial cell alignment in Matrigel in vitro and angiogenesis in vivo. Am J Physiol 1997; 273: C239-45.
• 51 Carmeliet P, Mackman N, Moons L, Luther T, Gressens P, Van Vlaenderen I. et al. Role of tissue factor in embryonic blood vessel development. Nature 1996; 383: 73-5.
• 52 Mueller BM, Reisfeld RA, Edgington TS, Ruf W. Expression of tissue factor by melanoma cells promotes efficient hematogenous metastasis. Proc Natl Acad Sei USA 1992; 89: 11832-6.
• 53 Esumi N, Fan D, Fidler IJ. Inhibition of murine melanoma experimental metastasis by recombinant desulfatohirudin, a highly specific thrombin inhibitor. Cancer Res 1991; 51: 4549-56.
• 54 Ott I, Fischer EG, Miyagi Y, Mueller BM, Ruf W. A role for tissue factor in cell adhesion and migration mediated by interaction with actin-binding protein 280. J Cell Biol 1998; 140: 1241-53.
• 55 Kakkar AK, Chinswangwatanakul V, Lemoine NR, Williamson RCN. Tissue factor expression modulates invasion of human pancreatic carcinoma cells. Brit J Surg 1996; 83: 689.
• 56 Clagett GP, Reisch JS. Prevention of venous thromboembolism in general surgical patients. Results of meta-analysis. Ann Surg 1988; 208: 227-40.
• 57 Cisek LJ, Walsh PC. Thromboembolic complications following radical retropubic prostatectomy. Influence of external sequential pneumatic compression devices. Urology 1993; 42: 406-8.
• 58 Gallus AS, Hirsh J, O’Brien SE, McBride JA, Tuttle RJ, Gent M. Prevention of venous thrombosis with small, subcutaneous doses of heparin. JAMA 1976; 235: 1980-2.
• 59 Kakkar VV, Cohen AT, Edmonson RA, Phillips MJ, Cooper DJ, Das SK. et al. Low molecular weight versus standard heparin for prevention of venous thromboembolism after major abdominal surgery. The Thromboprophylaxis Collaborative Group (see comments). Lancet 1993; 341: 259-65.
• 60 The European Fraxiparine study group. Comparison of a low molecular weight heparin and unfractionated heparin for the prevention of thrombosis in patients undergoing abdominal surgery. Brit J Surg 1988; 75: 1058-63.
• 61 Nurmohamed MT, Verhaeghe R, Haas S, Iriarte JA, Vogel G, van Rij AM. et al. A comparative trial of a low molecular weight heparin (enoxaparin) versus standard heparin for the prophylaxis of postoperative deep vein thrombosis in general surgery. Am J Surg 1995; 169: 567-71.
• 62 Koppenhagen K, Adolf J, Matthes M, Tröster E, Roder JD, Hass S. et al. Low molecular weight heparin and prevention of postoperative thrombosis in abdominal surgery. Thromb Haemost 1992; 67: 627-30.
• 63 Bergvist D, Burmark US. Flordal et al. Low molecular weight heparin started before surgery as prophylaxis against deep vein thrombosis: 2500 versus 5000 Xal units in 2070 patients. Br J Surgery 1995; 82: 496-501.
• 64 ENOXACAN Study Group. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a doubleblind randomized multicentre trial with venographic assessment. Br J Surg 1997; 84: 1099-103.
• 65 Warkentin TE, Levine MN, Hirsh J, Horsewood P, Roberts RS, Gent M. et al. Heparininduced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin (see comments). N Engl J Med 1995; 332: 1330-5.
• 66 Monreal M, Lafoz E, Olive A, del Rio L, Vedia C. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin. Thromb Haemost 1994; 71: 7-11.
• 67 Koch A, Bouges S, Ziegler S, Dinkel H, Daures JP, Victor N. Low molecular weight heparin and unfractionated heparin in thrombosis prophylaxis after major surgical intervention: update of previous meta-analyses. Br J Surg 1997; 84: 750-9.
• 68 Levine M, Hirsh J, Gent M, Arnold A, Warr D, Falanga A. et al. Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer (see comments). Lancet 1994; 343: 886-9.
• 69 Bona RD, Sivjee KY, Hickey AD, Wallace DM, Wajcs SB. The efficacy and safety of oral anticoagulation in patients with cancer. Thromb Haemost 1995; 74: 1055-8.
• 70 Levine M. Treatment of thrombotic disorders in cancer patients. Haemostasis 1997; 27 Suppl 1: 38-43.
• 71 Levine MN, Hirsh J, Gent M, Turpie AG, Cruickshank M, Weitz J. et al. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. Arch Intern Med 1994; 154: 49-56.
• 72 Hyers TM, Hull RD, Weg JG. Antithrombotic therapy for venous thromboembolic disease. Chest 1995; 108: 335-51.
• 73 Hull RD, Raskob GE, Pineo GF, Green D, Trowbridge AA, Elliott CG. et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis (see comments). N Engl J Med 1992; 326: 975-82.
• 74 Prandoni P, Lensing AWA, Buller HRE. Comparison of subcutaneous low molecular weight heparin with intravenous standard heparin in proximal deep vein thrombosis. Lancet 1992; 339: 441-5.
• 75 Koopman MM, Prandoni P, Piovella F, Ockelford PA, Brandjes DP, van der Meer J. et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group. N Engl J Med 1996; 334: 682-7.
• 76 Levine M, Gent M, Hirsh J. A comparison of low molecular weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep vein thrombosis. N Eng J Med 1996; 334: 677-81.
• 77 Prandoni P, Lensing AW, Cogo A, Cuppini S, Villalta S, Carta M. et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996; 125: 1-7.
• 78 Pini M, Aiello S, Manotti C, Pattacini C, Quintavalla R, Poli T. et al. Low molecular weight heparin versus warfarin in the prevention of recurrences after deep vein thrombosis. Thromb Haemost 1994; 72: 191-7.
• 79 Das SK, Cohen AT, Edmondson RA, Melissari E, Kakkar VV. Low-molecular-weight heparin versus warfarin for prevention of recurrent venous thromboembolism: a randomized trial. World J Surg 1996; 20: 521-6.
• 80 Zacharski LR, Henderson WG, Rickies FR, Forman WB, Cornell Jr CJ, Forcier RJ. et al. Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate. Final report of VA Cooperative Study. Cancer 1984; 53: 2046-52.
• 81 Lebeau B, Chastang C, Brechot JM, Capron F, Dautzenberg B, Delaisements C. et al. Subcutaneous heparin treatment increases survival in small cell lung cancer. “Petites Cellules” Group. Cancer 1994; 74: 38-45.
• 82 Green D, Hull RD, Brant R, Pineo GF. Lower mortality in cancer patients treated with low-molecular-weight versus standard heparin (letter). Lancet 1992; 339: 1476.
• 83 Kakkar AK, Williamson RC. Prevention of venous thromboembolism in cancer using low-molecular-weight heparins. Haemostasis 1997; 27 Suppl 1: 32-7.